Enlicitide vs Simvastatin
Written by Aaron CuhaReviewed Sep 2026
The short answer
A PCSK9 blocking pill against the statin most people are given. Enlicitide cut LDL cholesterol by 57 percent in 2,909 people, which is a blood fat number. Simvastatin cut deaths from any cause from 14.7 to 12.9 percent over five years in 20,536 high risk adults, which is a real health result. Those are different kinds of evidence, and the gap between them is the point of this page.
- Enlicitide people
- 2,909
- Enlicitide nulls
- 0
- Simvastatin people
- 24,980
- Simvastatin nulls
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA approved 2026 for lowering LDL ("bad") cholesterol. Prescription only.
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
Approved and widely used for high blood fats such as cholesterol, and to lower the risk of heart and blood vessel disease. No approval and no use related to ageing or lifespan.
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
EnlicitideEnlicitide decanoate (oral macrocyclic peptide PCSK9 inhibitor)
The first PCSK9 cholesterol drug you can swallow. In 2,909 people it cut LDL cholesterol by 57 percent. Until now, drugs of this kind were all shots.
Column B
SimvastatinSimvastatin, HMG-CoA reductase inhibitor
Mixed into mouse food at two doses from 9 months of age, simvastatin did not change how long mice lived, in males or females. In 20,536 high-risk adults, it cut deaths from any cause from 14.7 percent to 12.9 percent over five years. Both results are real. They answer different questions.
Side by side, on the facts we can check
| What we compare | Enlicitide | Simvastatin |
|---|---|---|
| Category | Metabolic | Longevity |
| FDA status | FDA approved 2026 for lowering LDL ("bad") cholesterol. Prescription only. | Approved and widely used for high blood fats such as cholesterol, and to lower the risk of heart and blood vessel disease. No approval and no use related to ageing or lifespan. |
| Half-life | Effective half-life around 14 hours; terminal half-life considerably longer | About 2 hours for the parent drug, though the effect on cholesterol synthesis outlasts plasma exposure, which is why it is dosed once daily. |
| Molecular weight | Approximately 1,722 Da | 418.6 Da. A small molecule, not a peptide. |
| How it works | It grabs PCSK9 and stops it from reaching the LDL receptor. PCSK9 normally marks those receptors for destruction. With it blocked, the liver keeps more receptors to pull LDL out of the blood. The pill works because its ring shape resists gut enzymes, and it is taken with a helper that boosts absorption. | It blocks an enzyme the liver uses to make cholesterol. With less cholesterol being made, the liver pulls more LDL, the so-called bad cholesterol, out of the blood. The same chemical pathway also makes other building blocks that cells use for signalling. Blocking those is thought to cause some side benefits, like less swelling in blood vessels. It is also the most likely cause of the muscle aches some people get on statins. The idea that statins slow ageing rested on those side benefits, not on the cholesterol drop. That is because lab mice do not get the clogged arteries statins prevent in people. |
| Studies in people | 3 | 2 |
| Evidence | Strong: 3 completed trials, 2,909 people given it | Strong: 2 completed trials, 24,980 people given it |
| Legal status, US | Prescription only; FDA approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Enlicitide and Simvastatin?
Enlicitide: The first PCSK9 cholesterol drug you can swallow. In 2,909 people it cut LDL cholesterol by 57 percent. Until now, drugs of this kind were all shots. Simvastatin: Mixed into mouse food at two doses from 9 months of age, simvastatin did not change how long mice lived, in males or females. In 20,536 high-risk adults, it cut deaths from any cause from 14.7 percent to 12.9 percent over five years. Both results are real. They answer different questions.
Which has stronger research evidence, Enlicitide or Simvastatin?
Each compound gets a band worked out from facts we counted, with the math shown. Enlicitide is Strong (3 completed trials, 2,909 people given it). Simvastatin is Strong (2 completed trials, 24,980 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Enlicitide and Simvastatin FDA-approved?
Enlicitide: FDA approved 2026 for lowering LDL ("bad") cholesterol. Prescription only.. Simvastatin: Approved and widely used for high blood fats such as cholesterol, and to lower the risk of heart and blood vessel disease. No approval and no use related to ageing or lifespan..
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.